Understand the source comparison
SS-31 Beginners Guide: Peptide Comparison
Researchers frequently ask how SS-31 compares to other mitochondrial-targeting compounds and peptide-based therapies. The table below compares mechanism, clinical evidence, and research applications. SS-31 (Elamipretide) Cardiolipin stabilization at inner mito
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Researchers frequently ask how SS-31 compares to other mitochondrial-targeting compounds and peptide-based therapies. The table below compares mechanism, clinical evidence, and research applications.
- SS-31 (Elamipretide)
- Cardiolipin stabilization at inner mitochondrial membrane; prevents cytochrome c dissociation
- Phase II trials in heart failure (TACTIC-HFpEF), myocardial infarction (EMBRACE STEMI), mitochondrial myopathy. Significant functional improvements
- Subcutaneous or IV infusion
- Requires exact amino-acid sequencing including non-natural Dmt residues; synthesis complexity limits supplier availability
- Only peptide with direct cardiolipin binding; best evidence for mitochondrial protection in ischemia-reperfusion injury
- CoQ10 (Ubiquinone)
- Electron carrier in respiratory chain; antioxidant scavenger
- Mixed results. Small benefit in heart failure, minimal effect in neurodegenerative disease
- Oral supplementation
- Poor bioavailability (2–4%); does not cross inner mitochondrial membrane efficiently
- Generic antioxidant; cannot stabilize cardiolipin or prevent cytochrome c release
- MitoQ
- Mitochondrial-targeted CoQ10 via triphenylphosphonium cation
- Phase II trial in hepatitis C, Parkinson's disease. Modest antioxidant effect, no functional endpoint improvement
- Functions as ROS scavenger only; does not address cardiolipin oxidation or electron transport organization
- Better bioavailability than CoQ10 but still indirect mechanism
- NAD+
- Cofactor for electron transport chain; substrate for sirtuins and PARPs
- Preclinical models show benefit; human trials underway for aging and metabolic disease
- Oral (NMN, NR precursors) or IV infusion
- Increases NAD+ availability but does not directly stabilize mitochondrial structure
- Supports mitochondrial function indirectly; synergistic with SS-31 but not a replacement
- MOTS-C Peptide
- Mitochondrial-derived peptide; enhances insulin sensitivity and AMPK activation
- Preclinical only. No human trials published as of 2026
- Subcutaneous injection
- Mechanism is metabolic signaling, not membrane stabilization
- Metabolic benefits via AMPK; different target than SS-31
- The bottom line: SS-31 is the only research peptide with published clinical evidence for cardiolipin stabilization and mitochondrial protection during acute injury. CoQ10, MitoQ, and NAD+ precursors support mitochondrial function indirectly but do not prevent cytochrome c dissociation or reduce ROS generation at the source.